Dichlorphenamide Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 50 mg
Reference Brands: Keveyis (USA/EU)
Category:
Neurology
Dichlorphenamide is available in Tablets
and strengths such as 50 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Dichlorphenamide is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Dichlorphenamide can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Dichlorphenamide, also known as diclofenamide, is a sulfonamide-based carbonic anhydrase inhibitor belonging to the meta-disulfamoylbenzene class. It is classified as a first-generation carbonic anhydrase inhibitor and has a long history of clinical use across multiple therapeutic areas. The drug works by inhibiting carbonic anhydrase enzymes, leading to alterations in electrolyte balance and cellular excitability.
Historically, dichlorphenamide was approved in the United States in 1958 under the brand name Daranide for the treatment of glaucoma, including acute angle-closure glaucoma. Over time, it was also found to be effective in certain cases of therapy-resistant epilepsy. Further clinical research later established its role in neuromuscular disorders.
In 2015, dichlorphenamide received approval in the United States as an orphan drug under the brand name Keveyis for the treatment of primary periodic paralysis, including both hypokalemic and hyperkalemic forms. By stabilizing muscle membrane excitability, it helps reduce the frequency and severity of paralytic attacks. Due to its pharmacological activity, dichlorphenamide is prescribed under specialist supervision with appropriate clinical monitoring.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing